Oliver WisemanMA FRCS (Urol)
Consultant Urologist

Lead Clinician for urinary stone disease. Training Programme Director for East of England
- Direct:
- +44 (0)1223 586593email
- NHS Secretary:
- +44 (0)1223 216344email
- Private Secretary:
- +44 01223 370962 (Cambridge Urology Partnership)email
- Special Interests:
Urinary stone disease
Male factor infertility
Oliver is the lead clinician for urinary stone disease. His other area of interest is male infertility.
Oliver qualified in medicine from The University of Cambridge. He did his specialist training in London, and has also worked in France, Sweden and New Zealand.
He has published widely on stone disease, and his main research interests are in the development of PROMs for stone disease, and developing and recruiting to multicentre studies looking at outcomes from stone surgery.
He is the Training Programme Director for urology registrars in the East of England. He has run and been invited to participate in national and international training conferences and training courses on stone surgery and male infertility.
He is a trustee and committee member of British Association of Urological Surgeons (BAUS), is on the committee of the BAUS Section of Endourology, and was on the organising committee for the World Congress of Endourology, which was held in London in 2015. He is the BAUS lead for the publication of national outcomes from PCNL.
He has been awarded the Golden Telescope by The British Association of Urological Surgeons in recognition of his achievements, and also been invited to be a committee member of the Awards and Medal Committee of The Endourological Society.
Publications
Doizi S, Kamphuis G, Giusti G, Hovgaard Andreassen K, Knoll T, Osther P, Scoffone C, Pérez-Fentes D, Proietti S, Wiseman O, De la Rosette J, Traxer O.
Prog Urol. 2016 Nov;26(13):754-755. doi: 10.1016/j.purol.2016.07.176. French. No abstract available.
2. Alpha blockers should no longer be used for ureteric stones.
Wiseman OJ, McClinton S.
Int J Surg. 2016 Dec;36(Pt D):657-659. doi: 10.1016/j.ijsu.2016.11.006. Review.
Doizi S, Kamphuis G, Giusti G, Andreassen KH, Knoll T, Osther PJ, Scoffone C, Pérez-Fentes D, Proietti S, Wiseman O, de la Rosette J, Traxer O.
World J Urol. 2016 Sep 26. [Epub ahead of print]
4. Which Is Better? “Live” Surgical Broadcasts vs “As-Live” Surgical Broadcasts.
Phan YC, Segaran S, Wiseman O, James P, Clayman R, Smith A, Rane A.
J Endourol. 2016 Sep;30(9):1022-8. doi: 10.1089/end.2016.0165.
5. Investigating upper urinary tract urothelial carcinomas: a single-centre 10-year experience.
Dev HS, Poo S, Armitage J, Wiseman O, Shah N, Al-Hayek S.
World J Urol. 2016 Apr 29. [Epub ahead of print]
6. In Vitro Assessment of Three Clinical Lithotripters Employing Different Shock Wave Generators.
Faragher SR, Cleveland RO, Kumar S, Wiseman OJ, Turney BW.
J Endourol. 2016 May;30(5):560-5. doi: 10.1089/end.2015.0662.
Withington J, Armitage J, Finch W, Wiseman O, Glass J, Burgess N.
J Endourol. 2016 Jan;30(1):13-23. doi: 10.1089/end.2015.0278. Review.
8. A man with rust coloured urine and normocytic anaemia.
Case S, Johnston TJ, O’Sullivan M, Thomas W, Wiseman OJ.
BMJ. 2015 May 1;350:h2113. doi: 10.1136/bmj.h2113.
9. Hospital Volume Does Not Influence the Safety of Percutaneous Nephrolithotomy in England: A Population-Based Cohort Study.Withington JM, Charman SC, Armitage JN, Cromwell D, Finch WD, Wiseman OJ, Irving S, Glass J, Burgess NA.J Endourol. 2015 Aug;29(8):899-906. doi: 10.1089/end.2015.0007.
Finch W, Masood J, Buchholz N, Turney BW, Smith D, Wiseman O.
J Endourol. 2015 Jul;29(7):821-9. doi: 10.1089/end.2014.0580.
Turney B, Robertson W, Wiseman O, Amaro CR, Leitão VA, Silva IL, Amaro JL.
Int Braz J Urol. 2014 Jul-Aug;40(4):507-12. doi: 10.1590/S1677-5538.IBJU.2014.04.09.
Ali JM, See TC, Wiseman O, Griffiths WJ, Jah A.
Transpl Int. 2014 Dec;27(12):e126-8. doi: 10.1111/tri.12387.
13. ‘Measurement for improvement not judgement’ — the case of percutaneous nephrolithotomy.
Withington J, Armitage J, Finch W, Hughes B, Glass JM, Wiseman OJ, Irving SO, Burgess NA.
BJU Int. 2015 Feb;115(2):181-3. doi: 10.1111/bju.12660.